Replies to post #263 on Zyla Life Sciences (fka ZCOR)

[bbotcs]

ksviking12: I hear U. My problem is that I lost more than enough money in VVUS, a start-up pharma, after their flagship drug was approved. Egalet already has revenues and has infrastructure to promote new drugs, though they are going to have to spend more. Maybe this stock would be a deal at $3 and high risk at $6. Super-high risk at $9, my entry point!